Articles by Daniel Marsh
Keel Infrastructure Plunges, Erasing Nearly All June Note Proceeds
Keel Infrastructure shares tumbled 13.66%, erasing about $447 million in market value, nearly equaling the $445.4 million net proceeds from its June convertible note offering.
Plug Power Drops Below 200-Day Moving Average as Liquidity Concerns Linger
Plug Power (NASDAQ:PLUG) fell 3.4% to $2.55 on Thursday, dropping below its 200-day moving average, as market attention remained fixed on the company's cash position rather than its Danish hydrogen milestone.
USPS Holiday Schedule Sparks Parcel Investor Caution Amid Market Split
USPS will shut down on July 4, with normal service resuming July 6. Parcel investors watch volume declines and revenue shifts, as markets close early.
Deltic Energy Share Discount Widens as AIM Thinness Tests Cash Offer
Deltic Energy shares remain below the 7.7p cash offer from NEO NEXT+, with thin AIM liquidity widening the bid spread. Peel Hunt trades reveal the real market gap.
TELUS shares hit new low as new CEO faces high-yield dividend challenge
TELUS shares dropped 1.77% to a new 52-week low of CA$14.71 on Thursday, as new CEO Victor Dodig takes the helm. The stock's dividend yield of 11.36% is more than double that of BCE and Rogers, highlighting the challenge of sustaining payouts.
BlackBerry Shares Retreat as Note Conversion Weighs on Valuation
BlackBerry shares dropped 8.8% as a convertible note conversion window opened, raising dilution concerns despite strong QNX revenue growth.
Big Tree Cloud Volume Surges 3.7x Float Before Holiday Break
Big Tree Cloud (DSY) surged 50.7% on volume 3.7 times its total shares, with no news catalyst. The stock's valuation now exceeds 40 times revenue.
Dow Leads Market Rally After Soft Jobs Data, Nears Record Close
The Dow Jones Industrial Average jumped 435 points after weaker-than-expected June jobs data eased rate-hike concerns, with the blue-chip index nearing a record close.
Regencell Bioscience Shares Slide 63% Below May Offering Price
Regencell Bioscience (NASDAQ:RGC) dropped 6.6% to $7.50, remaining 63.1% below its May offering price, despite a brief intraday rebound. Biotech ETFs gained.